Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2Article Published on 2021-09-202022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] Ad5 Ad5-nCoV adverse effects age antibody antibody production booster booster dose clinical trial COVID-19 COVID-19 infection Effects Factor generate group IgG ELISA immunized immunosuppressive individual induce median natural infection Neutralizing antibodies neutralizing antibody Patient quantified reactogenicity recruited response SARS-CoV-2 surrogate Test vaccination Vaccine [DOI] 10.3390/vaccines9091047 PMC 바로가기 [Article Type] Article
Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?Research Article Published on 2021-09-202022-10-28 Journal: PLoS ONE [Category] COVID-19, SARS, [키워드] 95% confidence interval adjusted adverse event Adverse reaction age antibody antibody production antibody unit blood sample BNT162b2 BNT162b2 vaccine calculated correlated geometric healthcare worker healthy IgG level injection Japanese log-transformed magnitude median Messenger RNA positively correlated predict Questionnaires reactogenicity reflect Sample size SARS CoV-2 severity Sex significantly spike spike IgG Vaccine virus spike protein [DOI] 10.1371/journal.pone.0257668 PMC 바로가기 [Article Type] Research Article
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Articles Published on 2021-09-112022-10-30 Journal: Lancet (London, England) [Category] COVID-19, [키워드] 95% CI Academy analyses antibodies antibody Antibody titre antibody titres AstraZeneca AZD1222 baseline boost booster ChAdOx1 nCoV-19 Chinese Clinical research Coalition Cohort Controlled trial Council country COVID-19 vaccine dose Efficacy ELISA Engineering enrolled extended interval finding first dose funding geometric mean titre IgG Immunity immunogenicity data induce Innovation IQR ISRCTN median Medical Science mononuclear cell network NIHR Oxford participant PBMC Peripheral blood persistence phase 2/3 prime-boost interval randomised controlled trial reactogenicity Registered remained Science second dose SFU significantly higher single dose South supply shortage T-cell Response T-cell responses T-cells responses the vaccine titre vaccination Vaccine Valley viral particle Volunteer [DOI] 10.1016/S0140-6736(21)01699-8 PMC 바로가기 [Article Type] Articles
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial아데노바이러스 벡터화 및 mRNA COVID-19 백신(Com-COV)을 사용한 이종 대 상동 프라임-부스트 일정의 안전성 및 면역원성: 단일 맹검, 무작위, 비열등성 시험Clinical Trial Published on 2021-09-042022-09-11 Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상, 진단, [키워드] (ChAdOx1 nCoV-19 Administered age anti-Spike IgG approved assigned AstraZeneca baseline blood test blood tests BNT BNT162b2 boost ChAd ChAdOx1 ChAdOx1 nCoV-19 Cohort Comorbidity comparison Concentration COVID-19 COVID-19 disease COVID-19 vaccine COVID-19 vaccines criteria dose Efficacy eight eligible eligible participant Eligible participants ELISA enrolled evaluate facilitate female participant force geometric mean geometric mean concentration geometric mean ratio GMR greater groups Heterologous heterologous prime-boost heterologous schedule heterologous schedules homologous homologous schedule hospitalisation immune immune responses immunisation immunogenicity immunology inferiority ISRCTN laboratory confirmation limit majority mRNA mRNA vaccine non-inferiority non-inferiority trial occurred Older participant per-protocol population Pfizer-BioNTech primary analysis primary endpoint prime-boost interval prime-boost intervals randomised Randomly reactogenic reactogenicity receive receiving recipient recruited referred to regimen Registered reported Safety safety analyses safety analysis SARS-CoV-2 anti-spike IgG SARS-COV-2 infection Serious Adverse Event seronegative serum single-blind subset Support Task Force the SARS-CoV-2 the vaccine These data Trial vaccination Vaccine Vaccines vectored vaccine was done [DOI] 10.1016/S0140-6736(21)01694-9 PMC 바로가기 [Article Type] Clinical Trial
Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccineObservational Study Published on 2021-09-012022-10-05 Journal: Ultrasound in obstetrics & gynecology : the offici [Category] 임상, [키워드] acute respiratory syndrome Administered Admission age arthralgia asked bleeding Blood BNT162b2 mRNA BNT162b2 vaccine calculated case-control study comparable complications control group coronavirus coronavirus disease COVID-19 COVID-19 vaccine death demographics determine dose doses effective evaluate fetal Fever first dose gestation Gynecology headache humoral immune response IgG Immunoglobulin in both group Infection information intensive care interquartile range less Local local pain median medication membrane Neonatal no significant difference Obstetric obstetric outcome offered outcome outcomes participant Patient Pfizer/BioNTech positive Pregnancy pregnant population pregnant women Preterm birth questionnaire Rash reactogenicity recruited Respiratory Support returned rupture SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 IgG second dose second vaccination serology serum serum sample severe fatigue Side effect significantly significantly lower significantly more Society study group study period the study group the vaccine two groups two-dose regimen Ultrasound uterine vaccination Vaccine vaccine dose women [DOI] 10.1002/uog.23729 PMC 바로가기 [Article Type] Observational Study
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial남아프리카에 HIV가 있거나없는 사람들의 SARS-COV-2에 대한 Chadox1 NCOV-19 (AZD1222) 백신의 안전성 및 면역 원성 : 무작위, 이중 맹검, 위약 대조, Phase 1B/2A 시험의 중간 분석Clinical Trial Published on 2021-08-172022-08-13 Journal: The Lancet. HIV [Category] MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 1B/2A trial 95% CI adverse event adverse events African Alanine alanine aminotranferase allocation concealment Antibody Response Antibody Units Antiretroviral therapy Asp614Gly wild-type AZD1222 B.1.351 baseline Beta Beta variant binding antibodies binding antibody unit booster booster response both groups ChAdOx1 ChAdOx1 nCov 19 ChAdOx1 nCoV-19 clinical COV005 criteria cross-reactive binding antibodies cross-reactive binding antibody cross-reactivity D614G demonstrated died domain dose double-blind elevated eligibility criteria enrolled enrolment Fever finding FIVE foundation full-length funding geometric mean geometric mean concentration GMC high responder high responders High-level binding antibody HIV HIV-negative hospital IgG responses immunogenicity in both groups increased risk individual individuals Innovation interim analysis Intervention less Medical Research Council Melinda Gate Melinda Gates n=36 nCoV neutralisation Neutralising activity outcome Pan participant Participants people with HIV person with HIV Placebo placebo-controlled plasma Primary immunogenicity analyses Primary immunogenicity analysis prime-boost regimen priming priming dose randomised Randomly reactogenicity receive Receptor-binding domain Registered registry responses responses against retained rising Safety SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens Serious Adverse Events seronegative seropositive serum IgG Seven severe COVID-19 South South Africa titre Trial unlikely Vaccine vaccine dose Viral Viral load wild-type wild-type Wuhan-1 Asp614Gly with HIV [DOI] 10.1016/S2352-3018(21)00157-0 PMC 바로가기 [Article Type] Clinical Trial
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of actionReview Article Published on 2021-08-162022-10-04 Journal: NPJ Vaccines [Category] 변종, 임상, [키워드] adenoviral vector Antigen antigen expression Antigen presentation category Characteristics COVID-19 COVID-19 vaccine distinguishing feature Final Genetic immune system immunology inactivated Modification mRNA mRNA vaccines Neutralizing antibodies pandemic protective antibody response reached reactogenicity RNA vaccines SARS-CoV-2 subunit vaccination Vaccine Vaccines viral spike protein widespread [DOI] 10.1038/s41541-021-00369-6 PMC 바로가기 [Article Type] Review Article
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 A phase 1 randomized clinical trialSARS-COV-2에 대한 mRNA- 지질 나노 입자 백신 후보의 안전성 및 면역 원성은 1 상 무작위 임상 시험Clinical Trial Published on 2021-08-102022-08-13 Journal: Wiener Klinische Wochenschrift [Category] MERS, SARS, 임상, 진단, [키워드] Belgium comparable convalescent sera CureVac CVnCoV CVnCoV dose CVnCoV doses CVnCoV vaccination dosage Dosage-dependent increases Dose-response elicited ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Escalation Frequency Germany Ghent group Hannover healthy IgG antibodies IgG antibody immune response immune responses immunogenicity increases in interim analysis intramuscular dose Lipid nanoparticle Lipid nanoparticles LNP Local local AEs Mild moderate Munich Neutralizing antibodies overlapped Phase 1 phase 1 study Placebo platform Protein randomized clinical trial RBD reactogenicity Receptor binding domain response Result S protein S‑protein Safe Safety SARS-CoV-2 SARS-CoV‑2 SARS-CoV‑2 neutralizing titer SARS-CoV‑2 neutralizing titers SARS-CoV‑2 S‑protein second dose sequence-optimized mRNA coding serious AEs seroconverted severity supplementary material systemic adverse event systemic adverse events systemic AEs Tübingen vaccination Vaccine vaccine candidate Volunteer was measured [DOI] 10.1007/s00508-021-01922-y PMC 바로가기 [Article Type] Clinical Trial
Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infectionCase Report Published on 2021-08-022022-10-28 Journal: Radiology Case Reports [Category] COVID-19, [키워드] Abnormalities Acute myocarditis Adverse reaction benefit BNT162b2 cardiac children complications COVID-19 doses Echocardiogram elevated first dose Health authority healthy Infection lower risk men Mild Moderna mRNA mRNA vaccines mRNA-1273 myocarditis occur of BNT162b2 Pain Pfizer-BioNTech reactogenicity reported resonance risk SARS-COV-2 infection second dose Side effect significantly Surveillance sweating Tachycardia the patient therapy Trial troponin vaccination Vaccine X-ray younger people [DOI] 10.1016/j.radcr.2021.07.082 PMC 바로가기 [Article Type] Case Report
Personalized health and the coronavirus vaccines—Do individual genetics matter?Review Published on 2021-07-262023-07-02 Journal: Bioessays [Category] SARS, [키워드] COVID‐19 HLA human polymorphism Immunogenetics reactogenicity Vaccines [DOI] 10.1002/bies.202100087 PMC 바로가기 [Article Type] Review